Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HYP083
MIFTS: 59

Hypopituitarism

Categories: Endocrine diseases, Genetic diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hypopituitarism

About this section

MalaCards integrated aliases for Hypopituitarism:

Name: Hypopituitarism 12 77 54 38 30 56 45 15 17 74
Pituitary Insufficiency 12 54
Pituitary Hormone Deficiency 12
Pituitary Hypofunction 12

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:9406
KEGG 38 H01700
MeSH 45 D007018
NCIt 51 C62591
SNOMED-CT 69 74728003
ICD10 34 E23 E23.0
UMLS 74 C0020635
Sources

Summaries for Hypopituitarism

About this section
NIH Rare Diseases : 54 Hypopituitarism occurs when the body has low levels of certain hormones made by the pituitary gland.  The pituitary gland normally makes several hormones (including growth hormone, thyroid stimulating hormone, adrenocorticotropic hormone, prolactin, follicle stimulating hormone and luteinizing hormone, vasopressin, and oxytocin).  These hormones are important for directing body growth and development, and for regulating blood pressure and metabolism.  Symptoms of this condition vary and depend on which hormones are affected.  Treatment depends on the cause of this condition; once the cause is corrected, medication (hormone replacement therapy) must be taken to provide the body with the normal amount of hormones.

MalaCards based summary : Hypopituitarism, also known as pituitary insufficiency, is related to pituitary hormone deficiency, combined, 1 and pallister-hall syndrome. An important gene associated with Hypopituitarism is PROP1 (PROP Paired-Like Homeobox 1), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and p70S6K Signaling. The drugs Hydrocortisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and testes, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Disease Ontology : 12 A pituitary gland disease characterized by the decreased secretion of one or more of the eight hormones normally produced by the pituitary gland.

Wikipedia : 77 Hypopituitarism is the decreased (hypo) secretion of one or more of the eight hormones normally produced... more...

Sources

Related Diseases for Hypopituitarism

About this section

Diseases in the Hypopituitarism family:

Familial Hypopituitarism

Diseases related to Hypopituitarism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 449)
# Related Disease Score Top Affiliating Genes
1 pituitary hormone deficiency, combined, 1 34.0 HESX1 LHX3 LHX4 POU1F1
2 pallister-hall syndrome 32.8 GLI2 IGF1
3 combined pituitary hormone deficiencies, genetic forms 32.5 GLI2 HESX1 LHX4 POU1F1 PROP1
4 sheehan syndrome 32.5 CRH IGF1 INS POMC PRL
5 lymphocytic hypophysitis 32.4 GH1 POMC
6 combined pituitary hormone deficiency 32.1 HESX1 LHX3 LHX4 POU1F1 PROP1
7 isolated growth hormone deficiency 31.7 GH1 GHRH HESX1 IGF1 POU1F1 PROP1
8 septooptic dysplasia 31.7 HESX1 LHX3 LHX4 POU1F1 PROP1 SOX3
9 pituitary hormone deficiency, combined, 2 30.9 GH1 HESX1 IGF1 LHX3 LHX4 POMC
10 isolated growth hormone deficiency type iii 30.5 HESX1 SOX3
11 hypothalamic disease 30.3 CRH GH1 GHRH GNRH1 POMC PRL
12 adenoma 30.2 GH1 IGF1 POMC PRL
13 diabetes insipidus 30.2 CRH INS POMC PRL
14 galactorrhea 30.1 IGF1 PRL
15 gigantism 30.0 GH1 GHRH PRL
16 slipped capital femoral epiphysis 30.0 IGF1 IGFBP3
17 isolated growth hormone deficiency, type ii 29.9 GH1 GHRH HESX1 IGF1 POU1F1
18 turner syndrome 29.8 GH1 IGF1 IGFBP3
19 isolated growth hormone deficiency, type ib 29.8 GH1 GHRH IGF1 IGFBP3
20 silver-russell syndrome 29.8 GH1 IGF1 IGFBP3
21 growth hormone deficiency 29.8 GH1 GHRH HESX1 IGF1 IGFBP3 SOX3
22 hypoadrenalism 29.8 CRH GH1 POMC
23 hyperthyroidism 29.8 GH1 INS PRL
24 functioning pituitary adenoma 29.7 GH1 POMC PRL
25 hypogonadotropism 29.7 GNRH1 PRL
26 kallmann syndrome 29.7 GNRH1 HESX1 LHX3 PROP1
27 adenohypophysitis 29.5 GH1 POMC PRL
28 secondary adrenal insufficiency 29.5 IGF1 IGFBP3 INS
29 hyperinsulinism 29.5 GH1 IGF1 IGFBP3 INS
30 pituitary apoplexy 29.4 GNRH1 INS POMC PRL
31 conn's syndrome 29.4 CRH GH1 POMC PRL
32 pseudovaginal perineoscrotal hypospadias 29.3 GNRH1 IGFBP3
33 borjeson-forssman-lehmann syndrome 29.3 HESX1 LHX3 LHX4 POU1F1 PROP1 SOX3
34 empty sella syndrome 29.3 GH1 GNRH1 IGF1 POMC PRL
35 pituitary carcinoma 29.3 CRH POMC PRL
36 pituitary hypoplasia 29.3 HESX1 LHX3 LHX4 POU1F1 PRL SOX3
37 chiasmal syndrome 29.3 GNRH1 POMC PRL
38 hyperprolactinemia 29.2 GH1 GNRH1 IGF1 POMC PRL
39 pituitary stalk interruption syndrome 29.0 GH1 HESX1 LHX4 POU1F1 PRL SOX3
40 acromegaly 29.0 GH1 GHRH IGF1 IGFBP3 INS POMC
41 craniopharyngioma 28.9 GH1 GNRH1 IGF1 INS POU1F1 PRL
42 pituitary tumors 28.9 GH1 IGF1 POMC POU1F1 PRL PROP1
43 hypothyroidism 28.8 GH1 HESX1 IGF1 IGFBP3 LHX3 POMC
44 amenorrhea 28.8 CRH GNRH1 POMC PRL
45 insulin-like growth factor i 28.5 GH1 GHRH IGF1 IGFBP3 INS PRL
46 anorexia nervosa 28.4 CRH GH1 GHRH IGF1 IGFBP3 POMC
47 chromophobe adenoma 28.3 GH1 GHRH GNRH1 INS POMC PRL
48 hyperpituitarism 28.1 GH1 GHRH IGF1 IGFBP3 INS POMC
49 gonadal disease 27.8 CRH GH1 GNRH1 IGF1 INS POMC
50 pituitary gland disease 27.0 CRH GH1 GHRH GNRH1 HESX1 IGF1

Graphical network of the top 20 diseases related to Hypopituitarism:



Diseases related to Hypopituitarism
Sources

Symptoms & Phenotypes for Hypopituitarism

About this section

MGI Mouse Phenotypes related to Hypopituitarism:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.37 CRH GHRH GLI2 GNRH1 HESX1 IGF1
2 growth/size/body region MP:0005378 10.29 CRH GHRH GLI2 GNRH1 HESX1 IGF1
3 homeostasis/metabolism MP:0005376 10.28 CRH GHRH GLI2 GNRH1 IGF1 IGFBP3
4 nervous system MP:0003631 10.17 CRH GHRH GLI2 GNRH1 HESX1 IGF1
5 integument MP:0010771 10.01 CRH GLI2 GNRH1 IGF1 IGFBP3 INS
6 liver/biliary system MP:0005370 9.91 CRH GHRH GNRH1 IGFBP3 INS POMC
7 hearing/vestibular/ear MP:0005377 9.85 GLI2 HESX1 IGF1 LHX3 POU1F1
8 reproductive system MP:0005389 9.85 GHRH GLI2 GNRH1 IGF1 INS LHX3
9 renal/urinary system MP:0005367 9.65 CRH GNRH1 IGF1 INS POMC
10 respiratory system MP:0005388 9.43 CRH GLI2 HESX1 IGF1 LHX4 PROP1
11 skeleton MP:0005390 9.23 CRH GLI2 GNRH1 IGF1 IGFBP3 INS
Sources

Drugs & Therapeutics for Hypopituitarism

About this section

Drugs for Hypopituitarism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 50-23-7 5754
2
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 50-03-3
3
Testosterone Approved, Experimental, Investigational Phase 4,Phase 2,Not Applicable 58-22-0, 481-30-1 6013 10204
4
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
5
Cosyntropin Approved Phase 4 16960-16-0 16129617
6
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838
7
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
8
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0
9
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
10
Tesamorelin Approved, Investigational Phase 4,Phase 2 218949-48-5
11 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Hydrocortisone hemisuccinate Phase 4,Phase 3,Not Applicable,Early Phase 1
15 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Not Applicable,Early Phase 1
16 Anti-Inflammatory Agents Phase 4,Not Applicable,Early Phase 1
17 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
18 insulin Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
19 Mitogens Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
20 Hydrocortisone-17-butyrate Phase 4,Not Applicable,Early Phase 1
21 Epinephryl borate Phase 4,Phase 3,Not Applicable
22 Androgens Phase 4,Phase 2,Not Applicable
23 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
24 Anabolic Agents Phase 4,Phase 2
25 Testosterone 17 beta-cypionate Phase 4,Phase 2
26 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Not Applicable
27 Growth Hormone-Releasing Hormone Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Adrenergic Agonists Phase 4,Phase 3
29 Autonomic Agents Phase 4,Phase 3
30 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
32 Adrenergic alpha-Agonists Phase 4,Phase 3
33 Adrenergic Agents Phase 4,Phase 3,Phase 2
34 Respiratory System Agents Phase 4
35 Vasoconstrictor Agents Phase 4
36 Anti-Asthmatic Agents Phase 4
37 Sympathomimetics Phase 4
38 Mydriatics Phase 4
39 Adrenergic beta-Agonists Phase 4
40 Bronchodilator Agents Phase 4
41
Zinc Approved, Investigational Phase 3,Not Applicable,Early Phase 1 7440-66-6 32051
42
tannic acid Approved Phase 3,Not Applicable 1401-55-4
43
Benzocaine Approved, Investigational Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
44
Mecasermin Approved, Investigational Phase 3,Not Applicable 68562-41-4
45
Anastrozole Approved, Investigational Phase 2, Phase 3 120511-73-1 2187
46
Clonidine Approved Phase 3 4205-90-7 2803
47
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
48
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
49 Hypoglycemic Agents Phase 3,Not Applicable,Early Phase 1
50 Estrogens Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 255)
# Name Status NCT ID Phase Drugs
1 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Unknown status NCT02976675 Phase 4
2 Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Unknown status NCT02908958 Phase 4
3 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Unknown status NCT02314676 Phase 4
4 Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency Completed NCT00490191 Phase 4 Somatropin
5 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Completed NCT00851942 Phase 4 Synacthen (Tetracosactrin)
6 Testosterone Gel Applied to Women With Pituitary Gland Problems Completed NCT00144391 Phase 4 Transdermal Testosterone gel
7 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia Completed NCT00140413 Phase 4 Nutropin AQ
8 Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation Completed NCT00360074 Phase 4 Thyroxin, Triiodothyronine
9 Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. Completed NCT03015909 Phase 4 Somatropin
10 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Completed NCT02311894 Phase 4 Somatropin
11 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
12 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
13 Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.) Completed NCT01605331 Phase 4 sustained-release recombinant human GH (SR-rhGH)
14 A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Completed NCT01157793 Phase 4 r-hGH;r-hGH
15 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4 somatropin;placebo
16 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
17 Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome? Completed NCT01298180 Phase 4 Growth hormone (Genotonorm® or Omnitrope®)
18 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
19 Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Completed NCT00990340 Phase 4
20 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
21 Growth Hormone and Glucose Metabolism Completed NCT00929799 Phase 4 recombinant human Growth Hormone (Genotropin® )
22 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
23 Growth Hormone and Endothelial Function in Children Completed NCT00373386 Phase 4 growth hormone
24 Easypod United States User Trial Completed NCT00689260 Phase 4
25 Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT00567385 Phase 4 somatropin
26 IGF1 Generation Test Completed NCT00145457 Phase 4
27 Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® Completed NCT00256126 Phase 4 Saizen;Saizen
28 A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Completed NCT00212758 Phase 4 Nutropin AQ
29 Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children Recruiting NCT03290235 Phase 4 PEG-somatropin
30 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Recruiting NCT03249480 Phase 4
31 Body Composition and Adipose Tissue in HIV Recruiting NCT03226821 Phase 4 Tesamorelin
32 Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I) Recruiting NCT02380235 Phase 4
33 Optimising Steroid Replacement in Patients With Adrenal Insufficiency Enrolling by invitation NCT03282487 Phase 4 Modified release hydrocortisone
34 Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency Terminated NCT01698944 Phase 4 somatropin
35 A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury Terminated NCT00638053 Phase 4
36 Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury Terminated NCT00555009 Phase 4 Genotropin;Placebo
37 Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury. Withdrawn NCT00432263 Phase 4 Genotropin (PN-180,307) Somatropin
38 Treatment of Children With Insufficient Secretion of Growth Hormone Unknown status NCT00271518 Phase 3 growth hormone (somatropin)
39 Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency Completed NCT01007071 Phase 3 Human Growth Hormone (1-134);Placebo
40 Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys Completed NCT00133354 Phase 2, Phase 3 Arimidex (Anastrozole);Placebo;Growth Hormone
41 Treatment of Adrenal Insufficiency in Children Completed NCT02720952 Phase 3 Infacort®
42 Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency Completed NCT03223025 Phase 3 CinnaTropin®;Nordilet®
43 A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency Completed NCT03075644 Phase 3 somapacitan;Norditropin
44 Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency Completed NCT02693522 Phase 3 somatropin;Eutropin
45 Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency Completed NCT02558829 Phase 3 Macimorelin;Insulin
46 A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency Completed NCT02382939 Phase 3 somapacitan;somatropin
47 Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. Completed NCT02229851 Phase 3 somapacitan;somatropin;placebo
48 A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Study (FE 999905 CS07) of Zomacton in Children With Growth Hormone Deficiency Completed NCT02173821 Phase 3
49 Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency Completed NCT01502124 Phase 3 somatropin;somatropin
50 Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children Completed NCT01495468 Phase 3

Search NIH Clinical Center for Hypopituitarism

Cochrane evidence based reviews: hypopituitarism

Sources

Genetic Tests for Hypopituitarism

About this section

Genetic tests related to Hypopituitarism:

# Genetic test Affiliating Genes
1 Hypopituitarism 30
Sources

Anatomical Context for Hypopituitarism

About this section

MalaCards organs/tissues related to Hypopituitarism:

42
Pituitary, Brain, Testes, Thyroid, Bone, Heart, Liver
Sources

Publications for Hypopituitarism

About this section

Articles related to Hypopituitarism:

(show top 50) (show all 1569)
# Title Authors Year
1
Ectopic acromegaly due to growth hormone-releasing hormone producing bronchial carcinoid causing somatotroph hyperplasia and partial pituitary insufficiency. ( 30608060 )
2019
2
Clinical characteristics and postoperative recovery of hypopituitarism in patients with nonfunctional pituitary adenoma. ( 30880207 )
2019
3
The autoimmune basis of hypopituitarism in traumatic brain injury: fiction or reality? ( 30653380 )
2019
4
Growth hormone replacement therapy improves hypopituitarism-associated hypoxemia in a patient after craniopharyngioma surgery: A case report. ( 30653131 )
2019
5
Truncating RAX mutations: anophthalmia, hypopituitarism, diabetes insipidus and cleft palate in mice and men. ( 30811539 )
2019
6
Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer. ( 30850565 )
2019
7
Genome-wide methylation study of whole blood cells DNA in men with congenital hypopituitarism disease. ( 30365064 )
2019
8
A novel GLI2 mutation responsible for congenital hypopituitarism and polymalformation syndrome. ( 30583238 )
2019
9
Slipped capital femoral epiphysis in an adult with congenital hypopituitarism: A case report. ( 30653105 )
2019
10
Oxytocin alterations and neurocognitive domains in patients with hypopituitarism. ( 30656597 )
2019
11
Liver Involvement in Congenital Hypopituitarism. ( 30666560 )
2019
12
Hypopituitarism following Cranial Irradiation for Meningiomas: A single-institution experience. ( 30731274 )
2019
13
Prolonged neonatal hyperbilirubinaemia in a case of congenital hypopituitarism. ( 30737331 )
2019
14
Congenital Hypopituitarism: Various Genes, Various Phenotypes. ( 30759489 )
2019
15
Improvements in body composition after 4 years of growth hormone treatment in adult-onset hypopituitarism compared to age-matched controls. ( 30844796 )
2019
16
Hypopituitarism Related Cholestatic Jaundice: Important to Recognise, Rewarding to Treat but Difficult to Diagnose! ( 30863924 )
2019
17
Hypothalamo-pituitary axis irradiation dose thresholds for development of hypopituitarism in adult-onset gliomas. ( 30873631 )
2019
18
Impaired EIF2S3 function associated with a novel phenotype of X-linked hypopituitarism with glucose dysregulation. ( 30878599 )
2019
19
A case series study of hypopituitarism in older patients with and without gastrointestinal symptoms. ( 29863435 )
2018
20
Congenital hypopituitarism: how to select the patients for genetic analyses. ( 29625578 )
2018
21
Prevalence and treatment of central hypogonadism and hypoandrogenism in women with hypopituitarism. ( 29789996 )
2018
22
Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis. ( 29752700 )
2018
23
Congenital Hypopituitarism. ( 29406008 )
2018
24
Rhabdomyolysis in a patient complicated with hypopituitarism and multiple organ dysfunction syndrome and the literature review. ( 29910183 )
2018
25
Chronic Hypopituitarism Associated with Increased Postconcussive Symptoms Is Prevalent after Blast-Induced Mild Traumatic Brain Injury. ( 29515515 )
2018
26
Pituitary in black-hypopituitarism secondary to hemosiderosis. ( 29549596 )
2018
27
Neonatal Hypopituitarism: Diagnosis and Treatment Approaches. ( 29739730 )
2018
28
Congenital Hyperinsulinism and Hypopituitarism Attributable to a Novel Mutation in FOXA2. ( 29329447 )
2018
29
Iatrogenic water intoxication in a female adolescent with hypopituitarism. ( 29523609 )
2018
30
Granular cell tumour of the neurohypophysis: an unusual cause of hypopituitarism. ( 29732160 )
2018
31
Pathogenic copy number variants in patients with congenital hypopituitarism associated with complex phenotypes. ( 29265571 )
2018
32
A case series of closed head trauma with pituitary stalk disruption resulting in hypopituitarism. ( 29477026 )
2018
33
DIFFERENTIAL REGULATION OF 11 I^ -HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVITY IN PATIENTS WITH DIFFERING AETIOLOGIES OF HYPOPITUITARISM. ( 29975580 )
2018
34
Hormone-replacement Therapy for Hepatopulmonary Syndrome and NASH Associated with Hypopituitarism. ( 29910217 )
2018
35
Bone safety of dual-release hydrocortisone in patients with hypopituitarism. ( 29313195 )
2018
36
Next generation sequencing panel based on single molecule molecular inversion probes for detecting genetic variants in children with hypopituitarism. ( 29739035 )
2018
37
Craniopharyngeal canal, morning glory disc anomaly and hypopituitarism: what do they have in common? ( 29977576 )
2018
38
Reduced Hepatocellular Expression of Canalicular Transport Proteins in Infants with Neonatal Cholestasis and Congenital Hypopituitarism. ( 29935878 )
2018
39
Metabolic Syndrome in Hypopituitarism. ( 29895033 )
2018
40
Prolactin-Producing Pituitary Carcinoma, Hypopituitarism, and Graves' Disease-Report of a Challenging Case and Literature Review. ( 29928263 )
2018
41
Intracranial germinoma causing cerebral haemiatrophy and hypopituitarism. ( 29378909 )
2018
42
Hypopituitarism After Single-Fraction Pituitary Adenoma Radiosurgery: Dosimetric Analysis Based on Patients Treated Using Contemporary Techniques. ( 29678524 )
2018
43
Anterior hypopituitarism in a patient with amyloidosis secondary to Crohn's disease: a case report. ( 29929552 )
2018
44
Cerebrofacial arteriovenous metameric syndrome with hypopituitarism: a rare association. ( 29330274 )
2018
45
Hypopituitarism 3 and 12 months after traumatic brain injury and subarachnoid haemorrhage. ( 29283287 )
2018
46
Neonatal hypoglycemia, early-onset diabetes and hypopituitarism due to the mutation in EIF2S3 gene causing MEHMO syndrome. ( 29303605 )
2018
47
Adrenal crisis presented as acute onset of hypercalcemia and hyponatremia triggered by acute pyelonephritis in a patient with partial hypopituitarism and pre-dialysis chronic kidney disease. ( 30456557 )
2018
48
Hypopituitarism after Gamma Knife surgery for postoperative nonfunctioning pituitary adenoma. ( 30544293 )
2018
49
Extrapontine Myelinolysis and Reversible Parkinsonism After Hyponatremia Correction in a Case of Pituitary Adenoma: Hypopituitarism as a Predisposition for Osmotic Demyelination. ( 30055367 )
2018
50
A neurosurgical approach to traumatic brain injury and post-traumatic hypopituitarism. ( 30483919 )
2018
Sources

Variations for Hypopituitarism

About this section
Sources

Expression for Hypopituitarism

About this section
Search GEO for disease gene expression data for Hypopituitarism.
Sources

Pathways for Hypopituitarism

About this section

Pathways related to Hypopituitarism according to KEGG:

38
# Name Kegg Source Accession
1 Neuroactive ligand-receptor interaction hsa04080

Pathways related to Hypopituitarism according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
p70S6K Signaling 65
Show member pathways
 12.76 GH1 GHRH GNRH1 IGF1 INS
2
G-Beta Gamma Signaling 65
Show member pathways
 12.72 CRH GH1 GHRH GLI2 POMC
3
NF-KappaB Family Pathway 65
Show member pathways
 12.45 GH1 GHRH GNRH1 IGF1
4
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 11.88 GH1 GHRH GNRH1 IGF1
5
G alpha (s) signalling events 67
11.85 CRH GHRH POMC
6
Adipogenesis 1
11.75 GH1 IGF1 INS
7
Immune response IFN gamma signaling pathway 23
Show member pathways
 11.75 GH1 GHRH GNRH1 IGF1
8
Senescence and Autophagy in Cancer 1
11.52 IGF1 IGFBP3 INS
9
G-protein signaling_RhoA regulation pathway 23
11.25 GH1 GHRH GNRH1 IGF1
10
Glucocorticoid receptor regulatory network 1
11.25 POMC POU1F1 PRL
11
Peptide hormone metabolism 67
Show member pathways
 11.18 GH1 IGF1 INS POMC
12
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 67
10.82 IGF1 IGFBP3
13
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 62
9.8 CRH POMC
Sources

GO Terms for Hypopituitarism

About this section

Cellular components related to Hypopituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 CRH GH1 GHRH GNRH1 IGF1 IGFBP3
2 extracellular space GO:0005615 9.61 CRH GH1 GHRH GNRH1 IGF1 IGFBP3
3 perikaryon GO:0043204 9.54 CRH GHRH GNRH1
4 insulin-like growth factor ternary complex GO:0042567 9.26 IGF1 IGFBP3
5 insulin-like growth factor binding protein complex GO:0016942 9.16 IGF1 IGFBP3
6 endosome lumen GO:0031904 8.8 GH1 INS PRL

Biological processes related to Hypopituitarism according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 GLI2 GNRH1 IGF1 LHX3 LHX4 PROP1
2 cell-cell signaling GO:0007267 9.84 GHRH GNRH1 INS POMC
3 cellular protein metabolic process GO:0044267 9.83 IGF1 IGFBP3 INS PRL
4 positive regulation of MAPK cascade GO:0043410 9.82 IGF1 IGFBP3 INS
5 animal organ morphogenesis GO:0009887 9.81 LHX3 LHX4 PROP1
6 positive regulation of cell proliferation GO:0008284 9.8 CRH GHRH GLI2 IGF1 INS POU1F1
7 female pregnancy GO:0007565 9.77 CRH GNRH1 PRL
8 lung development GO:0030324 9.76 CRH GLI2 LHX3
9 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.72 GH1 IGF1 INS
10 regulation of signaling receptor activity GO:0010469 9.7 GH1 GHRH GNRH1 IGF1 INS POMC
11 positive regulation of JAK-STAT cascade GO:0046427 9.65 GH1 PRL
12 motor neuron axon guidance GO:0008045 9.65 LHX3 LHX4
13 dorsal/ventral pattern formation GO:0009953 9.65 GLI2 LHX3 PROP1
14 positive regulation of glycolytic process GO:0045821 9.64 IGF1 INS
15 positive regulation of glycogen biosynthetic process GO:0045725 9.63 IGF1 INS
16 response to ethanol GO:0045471 9.62 CRH GNRH1
17 hypothalamus development GO:0021854 9.62 CRH SOX3
18 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.61 GH1 PRL
19 positive regulation of multicellular organism growth GO:0040018 9.61 GH1 GHRH POU1F1
20 somatotropin secreting cell differentiation GO:0060126 9.51 POU1F1 PROP1
21 adenohypophysis development GO:0021984 9.5 GHRH POU1F1 PROP1
22 positive regulation of lactation GO:1903489 9.46 GHRH PRL
23 medial motor column neuron differentiation GO:0021526 9.37 LHX3 LHX4
24 transcription by RNA polymerase II GO:0006366 9.3 POU1F1
25 parturition GO:0007567 9.27 CRH
26 ovulation cycle GO:0042698 9.26 GNRH1
27 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.26 GH1 GHRH IGF1 IGFBP3
28 pituitary gland development GO:0021983 9.02 GLI2 HESX1 LHX3 POU1F1 SOX3
29 regulation of transcription, DNA-templated GO:0006355 10.11 HESX1 INS LHX3 LHX4 POU1F1 PROP1
30 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 GLI2 IGF1 LHX3 LHX4 POMC POU1F1
31 positive regulation of transcription, DNA-templated GO:0045893 10 GHRH GLI2 IGF1 LHX3 POU1F1

Molecular functions related to Hypopituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.8 GLI2 HESX1 LHX3 LHX4 POU1F1 PROP1
2 chromatin binding GO:0003682 9.71 GLI2 HESX1 POU1F1 PROP1
3 sequence-specific DNA binding GO:0043565 9.63 GLI2 HESX1 LHX3 LHX4 POU1F1 PROP1
4 insulin receptor binding GO:0005158 9.37 IGF1 INS
5 insulin-like growth factor receptor binding GO:0005159 9.32 IGF1 INS
6 hormone activity GO:0005179 9.23 CRH GH1 GHRH GNRH1 IGF1 INS
7 prolactin receptor binding GO:0005148 8.96 GH1 PRL
Sources

Sources for Hypopituitarism

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....